Raphael Pharmaceutical (RAPH) Receivables - Net (2024 - 2025)
Raphael Pharmaceutical's (RAPH) quarterly Receivables - Net came in at $2000.0 in Q4 2025, little changed year-on-year from $2000.0 in Q4 2024, and little changed quarter-over-quarter from $2000.0 in Q4 2024.
Raphael Pharmaceutical (RAPH) Receivables - Net (2024 - 2025) Analysis & Trends
Raphael Pharmaceutical has disclosed Receivables - Net across 2 years of filings, most recently posting $2000.0 for Q4 2025.
- Receivables - Net for Q4 2025 came in at $2000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $2000.0 (changed 0.0% YoY), and the FY2025 annual result was $2000.0, changed 0.0% from the prior year.
- Receivables - Net came in at $2000.0 for Q4 2025 at Raphael Pharmaceutical, roughly flat from $2000.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $2000.0 in Q4 2024 to a low of $2000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Raphael Pharmaceutical | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Dec 31, 2024 | 2,000.00 |